市場調查報告書
商品編碼
1373374
全球骨科生物材料市場 - 2023-2030Global Orthopedic Biomaterials Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
生物材料是一種為了醫療目的(治療或診斷測試)而與生物系統相互作用的物質。生物材料可以在實驗室中使用多種化學技術使用金屬或聚合物成分、陶瓷或複合材料來製造,生物材料也可以從自然界中獲得。
骨科生物材料用於固定骨骼的暫時植入物、永久植入材料和生物可吸收植入物。常見的骨科生物材料包括磷酸鈣水泥、生物活性玻璃、聚合物、金屬和複合材料。
骨科手術數量的增加是市場成長的重要動力。在骨科手術中,生物材料可用於替換或再生受損或患病的組織,以改善其生理性能。
例如,美國關節置換登記處(AJRR) 發布的2022 年年度報告顯示,與前一年相比,整體累積手術量增加了14%,其中包括自2012 年以來來自1,250 多家醫院的超過280 萬例髖關節和膝關節手術、門診手術中心和私人執業團體。因此,對可用於骨科手術的生物材料的需求增加。
此外,據世界衛生組織稱,每年約有 2000-5000 萬人因道路傷亡而受到非致命傷害。同樣,根據 CDC 的數據,2020 年報告了大約 2,885,545 例非致命性損傷需要手術的門診病例。因此,由於這些損傷,骨科生物材料的使用增加,這有助於提振市場。
此外,類風濕性關節炎和骨關節炎等慢性疾病病例數量的增加以及產品的推出等重要的成長動力預計將在預測期內推動市場。
上市前批准和漫長的臨床試驗是適用於骨科生物材料市場的嚴格監管標準之一。這些昂貴且耗時的監管程序增加了整體開發成本,同時延遲了新型生物材料產品進入市場的時間。上述因素預計將阻礙市場成長。
A biomaterial is a substance that has been engineered to interact with biological systems for a medical purpose, either a therapeutic or a diagnostic test. Biomaterials can be created in the lab using a number of chemical techniques using metallic or polymeric components, ceramics, or composite materials, and biomaterials can also be obtained from nature.
Orthopedic biomaterials are used from temporary implants to fix bone to permanent implant materials and bioabsorbable implants. Common orthopedic biomaterials include calcium phosphate cements, bioactive glasses, polymers, metals, and composites.
The increasing number of orthopedic surgeries acts as a significant driver for market growth. In orthopedic surgeries, biomaterials can be utilized to replace or regenerate damaged or diseased tissues in order to improve their physiological performance.
For instance, the American Joint Replacement Registry (AJRR), published its 2022 annual report that demonstrates an overall cumulative procedural growth of 14% compared to the previous year and includes over 2.8 million hip and knee procedures since 2012 from over 1,250 hospitals, ambulatory surgery centers, and private practice groups. Hence, the demand for biomaterials increases that can be used in orthopedic surgeries.
Also, according to the WHO, approximately 20-50 million people get non-fatal injuries because of road casualties yearly. Likewise, according to the CDC, roughly 2,885,545 ambulatory cases were reported with non-fatal injuries requiring surgery in 2020. Thus, due to these injuries, the use of orthopedic biomaterials increased which help to boost the market.
Furthermore, significant growth drivers such as the growing number of cases of chronic diseases like rheumatoid arthritis, and osteoarthritis, and, product launches are expected to drive the market in the forecast period.
Pre-market approval and lengthy clinical trials are among the strict regulatory criteria that apply to the orthopedic biomaterial market. These expensive and time-consuming regulatory procedures raise the overall cost of development while delaying the release of novel biomaterial products into the market. The above factors are expected to hamper the market growth.
The global orthopedic biomaterials market is segmented based on material type, application, end users and region.
Calcium phosphate cement is a bioactive and biodegradable grafting material in the form of powder and liquid. Calcium phosphate cements are expected to hold the largest market share over the period forecast owing to increasing new orthopedic biomaterial launches and technical advancements.
For instance, in July 2022, Curasan AG launched the CERASORB CPC (Calcium Phosphate Cement) Bone Void Fillers for maxillofacial, orthopedic, and trauma surgery. CERASORB CPC is a synthetic, biocompatible, osteoconductive, and bioresorbable mineral bone cement composed of calcium and phosphate salts finely dispersed in a biocompatible oil.
Additionally, in May 2022, Granulab (M) Sdn Bhd launched Malaysia's first halal-certified synthetic bone cement called Prosteomax. It is an innovative calcium phosphate-based synthetic bone cement that has been certified halal by the Islamic Development Department Malaysia.
The global orthopedic biomaterials market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.
North America has maintained a significant market proportion due to factors such as the rising prevalence of orthopedic surgeries, and product launches, this trend is anticipated to continue throughout the forecast period.
For instance, in April 2023, Abyrx, Inc. received U.S. FDA clearances for the MONTAGE Settable, Resorbable Bone Putty as both a bone void filler and cranial bone cement. MONTAGE is a hand-moldable, hardening putty that, within minutes after mixing, develops bone-like characteristics and offers a unique intraoperative application.
Additionally, in February 2022, Orthofix Medical Inc. launched the Opus BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures. Opus BA can be used to fill skeletal system gaps or holes that are not essential to the stability of the bony structure.
The COVID-19 pandemic has had a significant impact on the global orthopedic biomaterials market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, biomaterial launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the orthopedic biomaterials market is expected to be moderately affected over the forecast period.
The major global players in the market include: Stryker Corporation, Koninklijke DSM N.V., Evonik Industries AG, Globus Medical, Zimmer Biomet Holdings Inc., Medbone, Invibio Ltd., CAM Bioceramics B.V., Exactech Inc., DePuy Synthes among others.
The global orthopedic biomaterials market report would provide approximately 61 tables, 63 figures, and 185 Pages.